Gri bio receives mhra authorization to conduct phase 2a biomarker study evaluating gri-0621 in the united kingdom

Mhra authorization expands ongoing u.s. phase 2a biomarker study evaluating lead program gri-0621 for the treatment of idiopathic pulmonary fibrosis (“ipf”) with interim data expected h1 2024 and topline data h2 2024
GRI Ratings Summary
GRI Quant Ranking